Hoberman Kenneth 4

What Happened
Kenneth Hoberman, a director of TG Therapeutics (TGTX), received a grant of 8,325 stock-tracking units (STUs) on June 11, 2026. The award was recorded with an acquisition price of $0 (derivative award). STUs are contingent rights that may convert into either one share of common stock or a cash payment equal to the share’s fair market value at the committee’s discretion.

Key Details

• Transaction date: 2026-06-11 (reported on Form 4 filed 2026-06-15). Filing appears timely (within SEC two-business-day window).
• Transaction type/code: A — Grant/Award of derivative securities (STUs).
• Quantity: 8,325 STUs; reported acquisition price $0.
• Shares owned after transaction: Not disclosed in the filing.
• Footnote F1: Each STU represents a contingent right to receive either one share of common stock or a cash payment equal to the fair market value of one share, to be paid no later than 30 days after the first anniversary of the grant (committee’s discretion).
• Footnote F2: Vesting condition — STUs vest on the first anniversary of the grant provided the reporting person remains in continuous service through the vesting date.

Context
This is a compensation grant (derivative award), not an open-market purchase or sale. Grants are common as director compensation and do not by themselves indicate insider buying or selling sentiment. The economic value to the recipient will depend on whether the committee elects stock or cash and on future stock price at vesting.